Portfolio Update

MERRILL LYNCH GREATER EUROPE INVESTMENT TRUST plc All information is at 31 January 2008 and unaudited. Performance at month end with net income reinvested One Three One Since Launch Month Months Year (20Sep04) Net asset value -12.2% -10.9% -0.9% 77.8% Share price -11.4% -12.1% -0.5% 71.4% FTSE World Europe ex UK -11.0% -10.2% 2.0% 70.1% Sources: BlackRock and Datastream At month end Net asset value (capital only): 171.47p Net asset value (including income): 171.40p* Share price: 165.00p *Includes net revenue of 0.07p Discount to NAV (capital only): 3.8% Discount to NAV (including income): 3.7% Gearing: 5.4% Net yield: 1.5% Total assets: £208.7m Ordinary shares in issue: 115,117,791 Benchmark Sector Analysis Total Assets Index (%) Country Analysis Total Assets (%) (%) Financials 28.1 28.1 Germany 19.6 Health Care 10.7 6.9 France 15.4 Basic Materials 9.4 6.9 Switzerland 12.6 Utilities 9.3 8.7 Italy 10.6 Consumer Goods 8.2 13.8 Netherlands 7.2 Telecommunications 7.4 7.3 Spain 5.2 Oil & Gas 7.3 6.2 Finland 4.8 Technology 6.1 4.4 Russia 4.0 Industrials 5.9 12.6 Emerging Europe 4.0 Consumer Services 3.3 5.1 Turkey 3.7 Other Investments 4.1 - Belgium 2.2 Net current assets 0.2 - Greece 1.9 Austria 1.7 Ireland 1.6 Norway 1.4 Luxembourg 1.1 Poland 1.0 USA 1.0 Israel 0.7 UK 0.1 Net current assets 0.2 ----- ----- ----- 100.0 100.0 100.0 ===== ===== ===== Ten Largest Equity Investments Company Country of Risk Banco Santander Spain Bayer Germany BlackRock Eurasian Frontiers Hedge Fund Emerging Europe Electricite de France France ENI Italy Intesa Sanpaolo Italy Nokia Finland Novartis Switzerland Roche Switzerland Siemens Germany Commenting on the markets, James Macmillan, representing the Investment Manager noted: European equity markets fell further in January with the FTSE World Europe ex UK Index (NDR) posting a decline of -11.0% in Sterling terms. Investors showed increasing concern that the US sub-prime crisis would negatively impact both economic and corporate growth in Europe. The most significant piece of news was the recognition by the US Federal Reserve and Government that the US economy was in need of support. This was delivered by a 0.75% rate cut on 22 January in an emergency session quickly followed by a further 0.50% cut on 31 January. The European Central Bank failed to follow the Fed's lead and kept borrowing costs at a six year high. Emerging Europe marginally outperformed the developed European markets but the MSCI Emerging Europe still posted a decline of -10.7% throughout January in Sterling terms as investors continued to be more cautious about the de-coupling of emerging and developed economies. The Company's NAV returned -12.2% underperforming the reference index. The contribution from the Emerging Europe region was marginally negative, with the benefit to the Company from its holding in the BlackRock Eurasian Frontiers Hedge Fund and also successful stock selection in Israel failing to offset the falls in Poland, Russia and Turkey. The Company's performance was adversely impacted by positive gearing in a falling market. During the month, the Company benefited from its exposure to defensive sectors, in particular Pharmaceutical stocks, Teva Pharmaceutical Industries and Roche, and Health Care stocks, Fresenius and Nobel Biocare, all delivering strong performance. Within the Technology sector companies, Capgemini, Ness Technologies and Nokia also boosted performance. Other positive contributors included selective investments in Real Estate, Capital Goods and Technology. The stocks which detracted from performance included our holdings in the Materials sector, including chemical company Lanxess and, in the Energy sector, Surgutneftegaz, as investors shied away from cyclical exposure. In addition, stock selection in the Materials, Consumer Durables & Apparel and Food, Beverage & Tobacco sectors was negative. During the month, the Company reduced its holdings in the Chemical, Mining, Utility and Pharmaceutical sectors. The sales proceeds were used to increase holdings in Financials through the purchase of shares in Bank, BNP Paribas and Insurance company, Zurich Financial Services Group and Telecoms, through Telecom Italia. The Company continues to have a bias towards financials, through Banks and Real Estate, along with Health Care, Materials and Technology. Exposure to Emerging Europe decreased during the month to finish at 13.4%, with the largest country exposures being Turkey and Russia, along with the BlackRock Eurasian Frontiers Hedge Fund which provides diversified exposure to the region. During the month the Company slightly increased its net market exposure to 105.4%. We remain positive on the prospects for European and Emerging European equities. Global economic growth is clearly moderating in response to a weaker US economy and the impact of higher credit costs, but central banks are determined to ensure stability in the world financial system by applying the appropriate monetary measures. At current prices, stocks carry attractive valuations and, we believe, will begin to respond positively once markets look forward to a resumption of stronger growth. Latest information is available by typing www.blackrock.co.uk/its on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). 25 February 2008
UK 100

Latest directors dealings